PMID- 36032110
OWN - NLM
STAT- MEDLINE
DCOM- 20220830
LR  - 20220831
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological 
      role in induction, regulation, and treatment.
PG  - 919973
LID - 10.3389/fimmu.2022.919973 [doi]
LID - 919973
AB  - Interleukin-18 (IL-18) is a potent pro-inflammatory cytokine involved in host 
      defense against infections and regulates the innate and acquired immune response. 
      IL-18 is produced by both hematopoietic and non-hematopoietic cells, including 
      monocytes, macrophages, keratinocytes and mesenchymal cell. IL-18 could 
      potentially induce inflammatory and cytotoxic immune cell activities leading to 
      autoimmunity. Its elevated levels have been reported in the blood of patients 
      with some immune-related diseases, including rheumatoid arthritis, systemic lupus 
      erythematosus, type I diabetes mellitus, atopic dermatitis, psoriasis, and 
      inflammatory bowel disease. In the present review, we aimed to summarize the 
      biological properties of IL-18 and its pathological role in different autoimmune 
      diseases. We also reported some monoclonal antibodies and drugs targeting IL-18. 
      Most of these monoclonal antibodies and drugs have only produced partial 
      effectiveness or complete ineffectiveness in vitro, in vivo and human studies. 
      The ineffectiveness of these drugs targeting IL-18 may be largely due to the 
      loophole caused by the involvement of other cytokines and proteins in the 
      signaling pathway of many inflammatory diseases besides the involvement of IL-18. 
      Combination drug therapies, that focus on IL-18 inhibition, in addition to other 
      cytokines, are highly recommended to be considered as an important area of 
      research that needs to be explored.
CI  - Copyright (c) 2022 Ihim, Abubakar, Zian, Sasaki, Saffarioun, Maleknia and Azizi.
FAU - Ihim, Stella Amarachi
AU  - Ihim SA
AD  - Department of Molecular and Cellular Pharmacology, University of Shizuoka, 
      Shizuoka, Japan.
AD  - Department of Pharmacology and Toxicology, University of Nigeria, Nsukka, 
      Nigeria.
AD  - Department of Science Laboratory Technology, University of Nigeria, Nsukka, 
      Nigeria.
FAU - Abubakar, Sharafudeen Dahiru
AU  - Abubakar SD
AD  - Division of Molecular Pathology, Research Institute for Biomedical Sciences, 
      Tokyo University of Science, Tokyo, Japan.
AD  - Department of Medical Laboratory Science, College of Medical Science, Ahmadu 
      Bello University, Zaria, Nigeria.
FAU - Zian, Zeineb
AU  - Zian Z
AD  - Biomedical Genomics and Oncogenetics Research Laboratory, Faculty of Sciences and 
      Techniques of Tangier, Abdelmalek Essaadi University, Tetouan, Morocco.
FAU - Sasaki, Takanori
AU  - Sasaki T
AD  - Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham 
      and Women's Hospital, Harvard Medical School, Boston, MA, United States.
AD  - Division of Rheumatology, Department of Internal Medicine, Keio University School 
      of Medicine, Tokyo, Japan.
FAU - Saffarioun, Mohammad
AU  - Saffarioun M
AD  - Biopharmaceutical Research Center, AryoGen Pharmed Inc., Alborz University of 
      Medical Sciences, Karaj, Iran.
FAU - Maleknia, Shayan
AU  - Maleknia S
AD  - Biopharmaceutical Research Center, AryoGen Pharmed Inc., Alborz University of 
      Medical Sciences, Karaj, Iran.
FAU - Azizi, Gholamreza
AU  - Azizi G
AD  - Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, 
      Karaj, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220811
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Cytokines)
RN  - 0 (Interleukin-18)
SB  - IM
MH  - Antibodies, Monoclonal
MH  - *Autoimmune Diseases/immunology
MH  - Cytokines
MH  - Humans
MH  - *Immunity
MH  - *Inflammation/immunology
MH  - *Interleukin-18/immunology
PMC - PMC9410767
OTO - NOTNLM
OT  - autoimmune diseases
OT  - immunity
OT  - inflammatory diseases
OT  - interleukin-18
OT  - monoclonal antibodies
COIS- Authors MS and SM were employed by AryoGen Pharmed Inc. The remaining authors 
      declare that the research was conducted in the absence of any commercial or 
      financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2022/08/30 06:00
MHDA- 2022/08/31 06:00
PMCR- 2022/01/01
CRDT- 2022/08/29 04:36
PHST- 2022/04/14 00:00 [received]
PHST- 2022/07/25 00:00 [accepted]
PHST- 2022/08/29 04:36 [entrez]
PHST- 2022/08/30 06:00 [pubmed]
PHST- 2022/08/31 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.919973 [doi]
PST - epublish
SO  - Front Immunol. 2022 Aug 11;13:919973. doi: 10.3389/fimmu.2022.919973. eCollection 
      2022.